Ensartinib (Ensartinib) complete instructions content official reference

As of2025July, ensartinib (Ensartinib) has not yet received drug registration approval in mainland China, so no official instructions have been released. The drug was developed by Chinese pharmaceutical company BeiGene and is mainly used to treat patients with ALK positive non-small cell lung cancer (NSCLC). At present, Ensartinib is not yet available in mainland China. If patients need to use it, they must purchase it through regular overseas channels. The following is drug information compiled based on existing public information for reference.

Ensartinib is an oral second-generation ALK inhibitor, structurally a thiazolopyrrolidone compound. Its mechanism of action is to specifically bind to the ALK kinase domain and inhibit its tyrosine kinase activity, thereby blocking the downstream signaling pathway mediated by the ALK fusion protein and inhibiting the proliferation and metastasis of tumor cells. In addition, ensartinib also has a strong inhibitory effect on ALK mutants (such as G1202R), showing the advantage of covering drug-resistant mutations.

In clinical trials, ensartinib has shown significant efficacy in ALKpositiveNSCLC patients. In a multicenter, open-label phase II clinical study, ensartinib achieved an objective response rate (ORR) of 67.7% and a disease control rate (DCR) of 96.2%. Median progression-free survival (PFS) was 12.9 months. In addition, the efficacy of ensartinib in patients with brain metastases has also been verified, showing good central nervous system penetration.

In terms of safety, the side effects of ensartinib are generally controllable. Common adverse reactions include fatigue, diarrhea, loss of appetite, nausea, abnormal liver function, etc. Most adverse reactions are mild to moderate and can be alleviated by symptomatic treatment. A small number of patients may experience serious adverse reactions such as prolongation of QT interval and severe abnormality of liver function, and should be used under the guidance of a doctor.

In general, ensartinib, as a new ALK inhibitor, is effective in ALKpositiveNSCLCshowed good efficacy and safety in the treatment. However, since it is not yet on the market in mainland China, patients who need to use it must purchase it through regular overseas channels and use it under the guidance of professional doctors. In the future, with the advancement of drug registration, ensartinib is expected to be launched in the Chinese market, providing new treatment options for ALK-positive NSCLC patients.

Reference materials:https://www.drugs.com/